Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Manu’s Minute: Structured Capital in Oklahoma

Get in Touch

‘Show Us the Money’

Editor’s note: This article was written by Manu Nair, vice president of Technology Ventures with the Oklahoma Medical Research Foundation

Friends and collaborators in industry often ask me about the availability of structured capital to fund biotech spin-offs in Oklahoma. It’s an astute question—but the answer might surprise you.

Historically, Oklahoma has had a problem with early-stage funding. Even when our state’s scientists generated promising new technologies, we had a hard time finding structured capital to transform those discoveries into successful commercial ventures.

But that all changed when i2E stepped into the void. For those of you who don’t know i2E, its mission is to invest in high-growth companies in Oklahoma. Initially structured as a State-backed funding mechanism, it has evolved into an investment fund managed by a private nonprofit.

Today, led by President and CEO Scott Meacham, i2E manages almost $60 million in investments, with more than $20 million in uninvested capital.

Over i2E’s 20-year history, it has made investments in more than 165 companies. Those investments have generated an internal rate of return of more than 30 percent, which compares favorably with just about any funding metric out there.

Forty percent of i2E’s portfolio is biotechnology, and over the years, it’s helped catalyze a series of successful companies in that space, including Novazyme (now a part of Sanofi), Crescendo Bioscience (acquired by Myriad Genetics) and Selexys Pharmaceuticals (purchased by Novartis). Each of those exits resulted in significant gains for i2E — and its investment partners.

You see, i2E takes a maximum of 50 percent in any investment round. That means it always needs partners. The process of bringing new parties into deals ensures outside validation of the business opportunity while also infusing the start-up with the expertise and resources these new investors can provide.

In the past, those partners have included Kleiner Perkins, MDV and MPM Capital. Recently, OCA Ventures and Mayo Clinic Ventures joined i2E in an initial financing round for OMRF spin-off Progentec, which is developing diagnostic and disease management tools for lupus.

For OMRF, i2E has proven to be a reliable and creative partner. For example, when we needed capital to fund a clinical trial of an experimental brain cancer treatment, i2E made the project possible through a non-traditional investment agreement. That faith and flexibility subsequently paid off: The trial generated promising results and led to a deal with Korean pharmaceutical company Oblato, Inc.

Going forward, i2E is poised to put its funds to use to catalyze nascent Oklahoma biotechs. And its successes have helped populate Oklahoma’s capital landscape with other early-stage funders. Together, they serve as a major asset to growing companies, helping attract both quality management and investment partners.

By giving start-up ventures access to structured capital, i2E is one more reason OMRF has proven time and again that we can commercialize our technologies successfully.

Author

  • Sarah Graves Sarah Graves

More News

Loading...
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
Default Featured Image
OKBio
06.13.22

AscendBioVentures BIO

Read more
Default Featured Image
OKBio
06.13.22

Dean McGee Eye Institute BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E